A double blind, double dummy study on the efficacy, tolerability and safety of
Parlodel LAR versus oral
Parlodel was carried out in 13 hyperprolactinemic women. Six patients received active from of
Parlodel LAR (1
intramuscular injection at a dose of 50 mg) and placebo for oral
Parlodel simultaneously. Seven other patients received active form of
Parlodel orally (up to 7.5 mg daily) and placebo for
Parlodel LAR injection. In all patients the marked reduction in serum
prolactin level was observed. In normalization of prolactinemia was achieved in 8 patients (2 LAR, 6 oral).
Galactorrhea disappeared in 7 of 8 patients (4 LAR, 3 oral), menstrual
bleeding occurred in 5 of 10 amenorrheic patients (3 LAR, 2 oral).
Tumor shrinkage was shown in 1 case (oral
therapy). The improvement of slightly narrowed visual field was documented in 3 cases (2 LAR, 1 oral). The adverse effect during the
therapy were mild and transient. We conclude that both froms of
bromocriptine are very useful for treatment of
hyperprolactinemia but
Parlodel LAR is better tolerated and more convenient in application because of its prolonged activity.